skin condition
Conditions
Interventions
Sponsors
Zhejiang Provincial People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Age 18–65 years inclusive (both inclusive); 2. Individuals seeking temporary improvement in facial skin dryness, dull complexion, and skin elasticity; 3. Skin Fitzpatrick type II–IV; 4. Voluntary participation in this trial and signing of the informed consent form; 5. Be willing to maintain the current skin care habits and not use other cosmetic treatments related to the study during the study period.
Exclusion criteria
Exclusion criteria: 1. Prone to keloid, hypertrophic scar, scar constitution or any other healing abnormality; 2. Allergic to the drugs involved in the trial (such as local anesthetic lidocaine or other amide narcotic drugs), the test products (hyaluronic acid), or known history of hypersensitivity reactions; 3. Coagulation dysfunction (APTT>1.5× ULN); Immune system diseases (such as systemic lupus erythematosus, scleroderma, etc.); Severe heart, liver and kidney diseases; 4. Skin diseases with active or advanced stage or isomorphous reaction in the treatment area, such as acute eczema, verruga plana, lichen planus, psoriasis vulgaris, etc. 5. Skin infection (including viral, bacterial, fungal), skin granuloma, malignant tumor or unknown skin mass in the treatment area, and unknown injection in the treatment area; 6. Receiving chemotherapy/radiotherapy; 7. Received any permanent or semi-permanent fillers (such as hydroxyapatite calcium, poly (L-lactic acid), polymethyl methacrylate, silicone, expanded polytetrafluoroethylene, polycaprolactone, etc.), autologous fat, and facial lifting surgery (including catgut-embedding) within 2 years; 8. Received other temporary fillers such as cross-linked hyaluronic acid or collagen injection therapy within 12 months; 9. Underwent facial surgery or cosmetic surgery, such as botulinum toxin injection, laser fractional therapy, radiofrequency therapy, ultrasound therapy, chemical exfoliation, skin dermabrasion, non-crosslinked hyaluronic acid injection, intense pulsed light, photon rejuvenation, etc. and received systemic retinoic acid treatment within 6 months; 10. Treatment with topical retinoic acid or corticosteroid in the trial area within 1 month; 11. Received any thrombolytic, anticoagulant or antiplatelet therapy (such as warfarin, aspirin, etc.) within 2 weeks; 12. Pregnant or lactating women and those who planned to have children during the study period; 13. Be known to be continuously using or expected to continue using photosensitive drugs or other treatments during the study; 14. Worked outdoors for a long time or needed to remove sunlight after surgery; 15. Combined with cognitive impairment or mental disorder, unable to understand and cooperate; 16. With too high expectation of treatment effect; 17. Participated in other clinical trials within 3 months before signing the informed consent; 18. Deemed by the investigator to be ineligible to participate in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement Rate on the Comprehensive Scale for Transient Alleviation of Skin Dryness and Dullness;Improvement rate of Allergan Skin Roughness Scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| Global Aesthetic Improvement Scale (GAIS);Evaluation of skin dullness improvement effect;Subject Satisfaction Scores;Allergan Fine Lines Scale (evaluated by blinded investigator);Allergan Skin Roughness Scale (evaluated by blinded investigator);the Comprehensive Scale for Transient Alleviation of Skin Dryness and Dullness;skin moisture content;skin elasticity; | — |
Countries
China
Contacts
Public ContactWu Sufan
Zhejiang Provincial People's Hospital
Outcome results
None listed